| 2026-03-02 |
详情>>
股本变动：
变动后总股本4868.23万股
|
| 2026-03-02 |
详情>>
业绩披露：
2025年年报每股收益-3.19美元,归母净利润-1.53亿美元,同比去年增长-20.98%
|
| 2026-03-02 |
财报披露：
美东时间 2026-03-02 盘前发布财报
|
| 2026-02-26 |
详情>>
内部人交易：
Robinson James A. Jr.股份增加2000.00股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.66美元,归母净利润-1.27亿美元,同比去年增长-42.26%
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-1.97美元,归母净利润-9378.3万美元,同比去年增长-42.77%
|
| 2025-07-15 |
股东大会：
将于2025-08-26召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following seven nominees presented by the Board of Directors to hold office until our next annual meeting of shareholders: Arie Belldegrun, M.D.; Elizabeth Barrett; Cynthia M. Butitta; Stuart Holden, M.D.; James A. Robinson, Jr.; Leana S. Wen, M.D., M.Sc.; Daniel G. Wildman;
2.To approve amendments to the Company’s 2024 non-employee director and officer compensation policy to, among other things, increase the equity compensation payable to our executive officers and non-employee directors;
3.To approve amendments to the Company’s 2017 Equity Incentive Plan to, among other things, increase the number of ordinary shares authorized for issuance under the plan by 2,750,000 shares;
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
5.To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers;
6.To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company’s auditor until the Company's 2026 annual meeting of shareholders;
7.In accordance with Israeli law, to discuss the Company's audited financial statements for the fiscal year ended December 31, 2024;
8.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2025-06-12 |
复牌提示：
2025-06-12 11:56:54 停牌，复牌日期 2025-06-12 14:00:00
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.92美元,归母净利润-4384.3万美元,同比去年增长-35.8%
|
| 2025-03-10 |
详情>>
业绩披露：
2024年年报每股收益-2.96美元,归母净利润-1.27亿美元,同比去年增长-24.09%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.36美元,归母净利润-8936.2万美元,同比去年增长-17.23%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-1.87美元,归母净利润-6568.9万美元,同比去年增长-20.87%
|
| 2024-07-01 |
股东大会：
将于2024-08-06召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until our next annual meeting of shareholders: Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, Fred E. Cohen, Stuart Holden, James A. Robinson, Jr., Leana S. Wen and Daniel G. Wildman;
2.To approve the Company’s 2024 non-employee director and officer compensation policy;
3.To approve an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 800,000 shares;
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
5.To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company’s auditor until our 2025 annual meeting of shareholders;
6.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.97美元,归母净利润-3228.6万美元,同比去年增长-6.86%
|
| 2024-03-14 |
详情>>
业绩披露：
2023年年报每股收益-3.55美元,归母净利润-1.02亿美元,同比去年增长6.87%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.89美元,归母净利润-7622.8万美元,同比去年增长5.79%
|
| 2023-08-01 |
股东大会：
将于2023-09-07召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following eight nominees presented by the Board of Directors to hold office until our next annual meeting of shareholders: Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, Fred E. Cohen, Stuart Holden, James A. Robinson, Jr., Leana S. Wen and Daniel Wildman;
2.To approve an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 450,000 shares;
3.To approve a grant of Performance Stock Units to the Company’s CEO under the Company's 2017 Equity Incentive Plan;
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
5.To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company’s auditor until our 2024 annual meeting of shareholders;
6.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2022-05-02 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following six nominees presented by the Board of Directors to hold office until the next annual meeting of shareholders: Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, Fred E. Cohen, Stuart Holden and Ran Nussbaum;
2.To approve an amendment to the Company’s amended and restated compensation policy for its office holders in accordance with the provisions of the Israeli Companies Law, 5759-1999;
3.To approve an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 400,000 shares;
4.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement;
5.To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company’s auditor until our 2023 annual meeting of shareholders;
6.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-07召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following eight nominees presented by the Board: Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, Fred E. Cohen, Kathryn E. Falberg, Stuart Holden, Ran Nussbaum and Shawn C. Tomasello;
2.To approve an amendment to the Company’s 2017 Equity Incentive Plan to increase the number of ordinary shares authorized for issuance under the plan by 400,000 shares
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
4.To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as the Company’s auditor until our 2022 annual meeting of shareholders;
5.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2020-04-29 |
股东大会：
将于2020-06-08召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following eight nominees presented by the Board: Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, Fred E. Cohen, Kathryn E. Falberg, Stuart Holden, Ran Nussbaum and Shawn C. Tomasello;
2.To approve an amendment to the Company’s 2017 Equity Incentive Plan to, among other things, increase the number of ordinary shares authorized for issuance under the plan by 400,000 shares;
3.To approve an amendment to the Company’s amended and restated compensation policy for its office holders in accordance with the provisions of the Israeli Companies Law, 5759-1999, or the Companies Law;
4.To approve terms of employment for Mark Schoenberg, Chief Medical Officer of the Company;
5.To approve the engagement of PricewaterhouseCoopers LLP, an independent registered public accounting firm as the Company’s independent auditor until our 2021 annual meeting of shareholders;
6.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
7.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2019-04-26 |
股东大会：
将于2019-06-03召开股东大会
会议内容 ▼▲
- 1.To elect to the Board of Directors the following eight nominees presented by the Board: Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, Fred E. Cohen, Kathryn E. Falberg, Stuart Holden, Ran Nussbaum and Shawn C. Tomasello;
2.To approve the Company’s amended and restated compensation policy for its office holders in accordance with the provisions of the Israeli Companies Law, 5759-1999, or the Companies Law;
3.To approve additional director cash compensation payment to Arie Belldegrun, M.D., FACS, a non-employee director and Chairman of the Board;
4.To approve a grant of options to Shawn C. Tomasello, a non-employee director;
5.To approve terms of employment for and a grant of options and restricted stock units to Elizabeth Barrett, President and Chief Executive Officer and director of the Company;
6.To approve terms of employment for and a grant of options and restricted stock units to Stephen L. Mullennix, Chief Operating Officer of the Company;
7.To approve the 2018 annual goals and objectives cash bonus payment to Ron Bentsur, former President and Chief Executive Officer and former director of the Company;
8.To approve the 2018 annual goals and objectives cash bonus payment to Stephen L. Mullennix, Chief Operating Officer of the Company;
9.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
10.To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company’s named executive officers;
11.To ratify the reappointment of Kesselman & Kesselman, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent auditor for the year ending December 31, 2019;
12.To conduct any other business properly brought before the annual meeting and any adjournment or postponement thereof.
|
| 2018-04-25 |
股东大会：
将于2018-06-04召开股东大会
会议内容 ▼▲
- 1.To reelect each of Arie Belldegrun, Ron Bentsur, Cynthia Buttita, Fred Cohen, Kathryn Falberg, Stuart Holden and Ran Nussbaum, as a director of the Company, to serve as a director and to hold office until the annual general meeting of shareholders to be held in 2019, subject to, and in accordance with, the provisions of the Israeli Companies Law, 5759-1999 (the “Companies Law”) and the articles of association of the Company, as amended from time to time;
2.To approve and ratify the reappointment of Kesselman & Kesselman, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent auditor for the year ending December 31, 2018 and until the next annual general meeting of shareholders, and to authorize the board of directors, upon recommendation of the audit committee, to determine the annual compensation of such independent registered accounting firm;
3.To approve grants of equity awards to our non-employee directors of the Company.
4.To act upon such other matters as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2018-01-11 |
股东大会：
将于2018-02-14召开股东大会
会议内容 ▼▲
- 1.To approve the Company’s compensation policy for its office holders in accordance with the provisions of the Israeli Companies Law, 5759-1999 (the “Companies Law”).
2.To approve a grant of options to Prof. Arie Belldegrun, M.D., a non-employee director and Chairman of the Company.
3.To approve a grant of options to Dr. Stuart Holden, M.D., a non-employee director of the Company.
4.To approve a grant of options to Dr. Pini Orbach, Ph.D., a non-employee director of the Company.
5.To approve a grant of options to Mr. Ran Nussbaum, a non-employee director of the Company.
6.To approve a grant of options to Ms. Kathryn Falberg, a non-employee director of the Company.
7.To approve a grant of options to Dr. Fred Cohen, M.D., a non-employee director of the Company.
8.To approve a grant of options to Ms. Cynthia Butitta, a non-employee director of the Company.
9.To approve terms of employment and a grant of options to Mr. Ron Bentsur, Chief Executive Officer and director of the Company.
10.To approve terms of employment and a grant of options to Mr. Gil Hakim, President of Israel Operation of the Company.
11.To approve terms of employment and a grant of options to Mr. Gary Titus, Chief Financial Officer of the Company.
12.To approve terms of employment and a grant of options and RSUs to Prof. Mark Schoenberg, M.D., Chief Medical Officer of the Company.
13.To approve 2017 annual goals and objectives bonus to Mr. Ron Bentsur, Chief Executive Officer and director of the Company.
14.To approve 2017 annual goals and objectives bonus to Mr. Gil Hakim, President of Israel Operation of the Company.
15.To approve 2017 annual goals and objectives bonus to Mr. Gary Titus, Chief Financial Officer of the Company.
16.To approve an amendment of the Officer Indemnity and Exculpation Agreements made and entered into by the Company and its directors and officers as of May 9th, 2017.
17.To act upon such other matters as may properly come before the Meeting or any adjournment or postponement thereof.
|